AU2019250832B2 - Dosing regimens for treatment of proliferative disorders - Google Patents

Dosing regimens for treatment of proliferative disorders Download PDF

Info

Publication number
AU2019250832B2
AU2019250832B2 AU2019250832A AU2019250832A AU2019250832B2 AU 2019250832 B2 AU2019250832 B2 AU 2019250832B2 AU 2019250832 A AU2019250832 A AU 2019250832A AU 2019250832 A AU2019250832 A AU 2019250832A AU 2019250832 B2 AU2019250832 B2 AU 2019250832B2
Authority
AU
Australia
Prior art keywords
curcumin
dmpc
dmpg
lysophosphatidylcholine
curcuminoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019250832A
Other languages
English (en)
Other versions
AU2019250832A1 (en
Inventor
Peter Sordillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of AU2019250832A1 publication Critical patent/AU2019250832A1/en
Application granted granted Critical
Publication of AU2019250832B2 publication Critical patent/AU2019250832B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019250832A 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders Active AU2019250832B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655095P 2018-04-09 2018-04-09
US62/655,095 2018-04-09
PCT/US2019/024495 WO2019199469A1 (en) 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
AU2019250832A1 AU2019250832A1 (en) 2020-10-29
AU2019250832B2 true AU2019250832B2 (en) 2022-10-27

Family

ID=68164516

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019250832A Active AU2019250832B2 (en) 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders

Country Status (11)

Country Link
US (2) US11813356B2 (https=)
EP (1) EP3773529B1 (https=)
JP (2) JP7241426B2 (https=)
KR (2) KR20240027843A (https=)
CN (1) CN112272555A (https=)
AU (1) AU2019250832B2 (https=)
CA (1) CA3096591C (https=)
ES (1) ES3061642T3 (https=)
MX (1) MX2020010651A (https=)
TW (1) TWI737974B (https=)
WO (1) WO2019199469A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
EP4675742A1 (en) 2023-02-28 2026-01-07 Panasonic Intellectual Property Management Co., Ltd. Non-aqueous electrolyte secondary battery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117186A1 (en) * 2009-11-19 2011-05-19 Lawrence Helson Intravenous infusion of curcumin and a calcium channel blocker
US20130337488A1 (en) * 2012-06-14 2013-12-19 Signpath Pharma Inc. Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244448B2 (en) * 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US8563525B2 (en) * 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
CN1973834A (zh) * 2006-12-15 2007-06-06 中国科学院长春应用化学研究所 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用
PT2146721E (pt) 2007-05-15 2013-07-18 Otsuka Pharma Co Ltd Métodos de utilização de antagonistas da vasopressina com agentes quimioterapeuticos de antraciclina para reduzir a cardiotoxicidade e/ou melhorar a sobrevivência
CN101766619B (zh) * 2008-12-30 2011-08-24 武汉大学 一种治疗恶性肿瘤的药物组合物及应用
DE112013004278T5 (de) * 2012-08-31 2015-05-21 Signpath Pharma Inc. Curcumin-Er, ein liposomales PLGA-Nanocurcumin mit verlängerter oder verzögerter Freisetzung zur Minimierung der QT-Verlängerung für eine Krebstherapie
US20150147385A1 (en) * 2013-11-22 2015-05-28 Signpath Pharma, Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
JP6895252B2 (ja) * 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
KR101755245B1 (ko) 2015-08-12 2017-07-07 연세대학교 원주산학협력단 단량체 염을 이용한 폴리이미드 복합체 제조방법
CA2940470C (en) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117186A1 (en) * 2009-11-19 2011-05-19 Lawrence Helson Intravenous infusion of curcumin and a calcium channel blocker
US20130337488A1 (en) * 2012-06-14 2013-12-19 Signpath Pharma Inc. Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANGELA STORKA et al., "Safety and pharmacokinetics of liposomal curcumin in healthy subjects:A randomized placebo controlled double blind first-in human study"104th Annual Meeting of the American Association for Cancer Research, (2013) *
Lee, Y. and Thompson, D.H."Stimuli-responsive liposomes for drug delivery" WIREs Nanomed Nanobiotechnol 2017, 9:e1450. doi: 10.1002/wnan.1450 *
Vahed, S.Z et al.:" Liposome-based drug co-delivery systems in cancer cells", Materials Science and Engineering: C, Volume 71, 1 February 2017, Pages 1327-1341 *

Also Published As

Publication number Publication date
ES3061642T3 (en) 2026-04-06
CA3096591C (en) 2023-06-27
JP7241426B2 (ja) 2023-03-17
US20240050372A1 (en) 2024-02-15
CN112272555A (zh) 2021-01-26
US11813356B2 (en) 2023-11-14
EP3773529C0 (en) 2025-12-24
EP3773529A1 (en) 2021-02-17
EP3773529B1 (en) 2025-12-24
TWI737974B (zh) 2021-09-01
JP2023030106A (ja) 2023-03-07
KR102637598B1 (ko) 2024-02-16
AU2019250832A1 (en) 2020-10-29
JP2021521130A (ja) 2021-08-26
WO2019199469A1 (en) 2019-10-17
TW201946613A (zh) 2019-12-16
KR20240027843A (ko) 2024-03-04
US12551436B2 (en) 2026-02-17
KR20200141062A (ko) 2020-12-17
US20210161815A1 (en) 2021-06-03
EP3773529A4 (en) 2021-12-22
MX2020010651A (es) 2021-01-15
CA3096591A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
Greil et al. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
JP6861682B2 (ja) コエンザイムＱ１０（ＣｏＱ１０）の静脈内投与用製剤およびその使用方法
JP6731336B2 (ja) コエンザイムｑ１０併用療法を用いた癌の処置方法
US12551436B2 (en) Dosing regimens for treatment of proliferative disorders
JP2024099034A (ja) １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
US20080103213A1 (en) Liposomal curcumin for treatment of neurofibromatosis
US20140037715A1 (en) Disulfiram formulation and uses thereof
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
JP2023532789A (ja) リポソーム製剤
CN115364218A (zh) 一种特定药脂比的药物组合物在抗肿瘤中的应用
US20150147385A1 (en) Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
CN121003588A (zh) 一种复方脂质体、冻干粉针剂及其制备方法、应用
HK40044373A (en) Dosing regimens for treatment of proliferative disorders
TWI607766B (zh) 核酸、醫用奈米粒子組以及醫藥組合物
US20210338583A1 (en) Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy
KR101735284B1 (ko) 젬시타빈이 포집된 면역 리포좀 및 베바시주맙을 유효성분으로 포함하는 교모세포종 예방 및 치료용 약학적 조성물
HK1133398A1 (en) Liposome formulation of mitoxantrone and method for preparation thereof
BR102013005601B1 (pt) Composição farmaceutica contendo lipossomas convencionais e lipossomas de circulaqao prolongada para o tratamento da leishmaniose visceral
HK1133398B (en) Liposome formulation of mitoxantrone and method for preparation thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)